

# **Trends, Risk Factors, and Comparison with Surgery for Early Stroke after TAVR – Reports from PARTNER and TVT Registry (in High- & Intermediate-Risk pts)**

---

**Samir Kapadia, MD**  
**Professor of Medicine**  
**Chairman, Department of Cardiology**  
**Cleveland Clinic**


# Disclosures

- **No financial disclosure**
- **National Co-PI for the Sentinel trial**


# Topics

- **Trends (TVT Registry)**
- **Risk Factors**
- **Comparison With SAVR**

# Post-TAVR 30-Day Stroke Rates Declining Major Clinical Trials



# TVT data Analysis



# Stroke Events Adjudication

Characteristic	% of Stroke Events
Neuroimaging performed	98.7%
Neurologist / neurosurgeon confirmation of diagnosis	93.8%
Symptom duration >24 hours	82.3%
Social activities impaired	48.6%
Neurocognitive function impaired	34.5%
New aid or assistance required	41.2%
Death as a result of stroke/TIA	11.3%

# 30-Day Neurologic Events

**Study Population  
N=101,430 patients**

**Any 30-Day Stroke  
N=2290**

**Any stroke 2.3%**  
**Ischemic stroke 2.1%**  
**Hemorrhagic stroke 0.1%**  
**Undetermined stroke 0.1%**  
**TIA 0.4%**

**No 30-Day Stroke  
N=99,140**

# Baseline Characteristics


Characteristic	Overall N=101,430	30-Day Stroke N=2290	No 30-Day Stroke N=99,140	P
Age (years)	83 (76, 87)	84 (78, 88)	82 (76, 87)	<.001
Female	47%	55%	47%	<.001
Prior Stroke	12%	17%	12%	<.001
Prior TIA	9%	14%	9%	<.001
Porcelain Aorta	5%	6%	5%	.008
PAD	30%	35%	30%	<.001
Atrial Fib/Flutter	40%	41%	40%	.493
Carotid Stenosis	20%	24%	20%	<.001




# Procedural Characteristics

Characteristic	Overall N=101,430	30-Day Stroke N=2290	No 30-Day Stroke N=99,140	P
Valve type				
- Self Expanding	26%	33%	26%	<.001
- Balloon Expandable	74%	67%	74%	
Access type				
- Femoral	84%	77%	84%	<.001
- Apical/aortic	13%	17%	13%	
- Other	3%	6%	3%	
General Anesthesia	76%	79%	76%	<.001
In-Hospital AF	4%	8%	4%	<.001


# Trends in Post-TAVR Neurologic Event Rates




# Timing of 30-Day Stroke




# Stroke by Access Type




# Risk Factors for Stroke (Femoral Cohort)




# Risk Factors for Stroke (Non-Femoral Cohort)



# Association of Post TAVR Stroke with Discharge Destination



# Association of Post TAVR Stroke with Mortality





# Summary of Observations


- The rate of 30-day stroke has not declined in the first 5 years of TAVR in US practice
- Stroke is associated with increased morbidity and mortality
- Procedural stroke (within 3 days) accounts for 68% of 30 day strokes
- Early stroke is lower in TF vs. alternative access TAVR

# Topics

- **Trends (TVT Registry)**
- **Risk Factors**
- **Comparison With SAVR**


# PARTNER 1A

## Raised Concern of Increased Neurologic Risk of TAVR



# PARTNER Trial Analysis


**April 2007 – October 2015**



*Final Propensity Matched Study Population*

	As Treated	PARTNER 1	PARTNER 2	S3	Total	<i>Median Follow-up</i>
TF-TAVR	406	602	196	1204	<i>SAVR: 2 years</i>	
SAVR	306	898	0	1204	<i>TF-TAVR: 1.5 years</i>	


# TF-TAVR Devices Propensity Matched Study Population



# Baseline Characteristics

Characteristic	SAVR (n = 1204)	TF-TAVR (n=1204)	p-value
Age - yrs	82 ± 6.7	82 ± 7.9	0.10
Female	45%	44%	0.9
CAD - %	69%	70%	0.6
Previous MI - %	20%	20%	0.8
Prior PCI - %	28%	28%	>0.9
Prior CABG - %	30%	31%	0.6
Prior BAV - %	6.4%	3.6%	0.003
Cerebrovascular Disease - %	31%	33%	0.4
Prior Stroke - %	12%	12%	0.8
Peripheral Vascular Disease - %	43%	45%	0.4


# 30-Day Neurologic Events




# Early Phase Risk (<7 Days)

## Instantaneous Risk Modeling

### Stroke



### Stroke or TIA







# Late Phase Risk (4 Years)

## *Instantaneous Risk Modeling*

### **Stroke**




### **Stroke or TIA**




# Cumulative Incidence of Events

*Adjusted for Competing Risk of Mortality*

## Stroke




## Stroke or TIA



# Association of Postoperative AV Gradients and Late Stroke Risk

- Increasing post-procedure mean trans-AV gradient was not associated with risk of stroke ( $P > 0.7$ ).
- No interaction of AV gradient and procedure type with risk of stroke ( $P$  interaction  $> 0.2$ ).

# Association of Stroke and 1 Year Quality of Life



# Principal Findings

1. 30-day major stroke risk lower in TF-TAVR compared to SAVR.
2. Similar pattern of early-peaking (<24 hours) and nearly constant late neurologic risk between SAVR and TF-TAVR.
3. No association with increasing valve gradients and late-phase stroke risk.
4. Major, but not minor, strokes are associated with lower QOL at 1-year.